Fierce Pharma1d
Sanofi's versatile Qfitlia scores FDA nod to enter crowded hemophilia market
Over the last three years, the FDA has approved six new hemophilia drugs, including three gene therapies. | Over the last ...
BlackDoctor.org3d
After Safe Trials, This Drug Was Approved for ATTR-CM
Amvuttra operates via RNA interference (RNAi), a groundbreaking technology that inhibits the production of the TTR protein in ...
Zacks Investment Research on MSN3d
Biotech Stock Roundup: SAVA Dives on Setback, ALNY Up on Update & More
It was a busy week in the biotech sector with important regulatory and pipeline updates. Among these, Cassava Sciences, Inc ...
FDA approves new drug to treat protein buildup in the heart
The FDA has approved a new drug for a serious heart condition that affects thousands of people. The drug, called Amvuttra ...
Alnylam Pharmaceuticals Presents 'Convincing Multi-Billion Dollar Opportunity': Analyst Upgrades Stock
CM, expanding its market reach. JP Morgan upgrades the stock, projecting strong sales and a multi-billion opportunity.
FDA OKs Amvuttra To Treat Heart Conditions
ATTR-CM is a disease in which harmful proteins build up in the heart, making it harder to pump blood, according to the ...
Zacks Investment Research on MSN5d
Alnylam (ALNY) Surges 11.8%: Is This an Indication of Further Gains?
Alnylam Pharmaceuticals (ALNY) shares soared 11.8% in the last trading session to close at $283.34. The move was backed by solid volume with far more shares changing hands than in a normal session.